Compare GNLX & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | CVRX |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.0M | 139.8M |
| IPO Year | 2022 | 2021 |
| Metric | GNLX | CVRX |
|---|---|---|
| Price | $3.01 | $5.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.25 | $10.50 |
| AVG Volume (30 Days) | 145.4K | ★ 227.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $2.29 | $4.37 |
| 52 Week High | $8.54 | $11.30 |
| Indicator | GNLX | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 44.79 |
| Support Level | $2.74 | $4.59 |
| Resistance Level | $2.98 | $5.96 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.75 | 24.60 |
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.